#Samsung flow alternative series#

How much further Retacrit will penetrate the renal market before a novel HIF-PH inhibitor is FDA approved will be a key determinate on uptake of this new class. While approved biosimilars are likely a few years off in neurology, early perceptions are tracked for a baseline into the potential impact on Biogen's Tysabri (natalizumab) and the current impact of off-label use of rituximab biosimilars (Pfizer's Ruxience, Teva/Celltrion's Truxima, and Amgen's Riabni).ДЇinally, Pfizer's Retacrit, a biosimilar of Amgen's Epogen and Janssen's Procrit, has substantially increased in use across nephrology settings, for both dialysis and non-dialysis. This service will also be Spherix's foray into their newest therapeutic area, ophthalmology, with expanded coverage in 2022 including the launch tracking of biosimilars of ranibizumab (Roche's Lucentis): Samsung Bioepis and Biogen's Byooviz and Coherus BioSciences' FYB201 вЂ“ the first biosimilars poised to enter this therapeutic area. Spherix currently tracks US utilization of Pfizer's Inflectra, Merck's Renflexis, and Amgen's Avsola (each biosimilars to Janssen's infliximab/Remicade) via their RealTime Dynamixв„ў quarterly market trackers but with Humira's patent expiry quickly approaching and a host of biosimilars pending 2023 launch (Amgen's Amjevita, Boehringer Ingelheim's Cyltezo, Sandoz's Hyrimoz, Merck's Hadlima, Pfizer's Abrilada, and Mylan's Hulio, to name a few), the importance of tracking the evolution of biosimilar perceptions will only continue to increase.

#Samsung flow alternative series#

The series will continue in 2022 on a semiannual basis and focus specifically on the autoimmune indications where biosimilar entry will play a large role in the next few years. The inaugural research included in Special Topixв„ў: Biosimilars Today and Tomorrow (US) will publish this month and will include six different reports in dermatology, gastroenterology, rheumatology, ophthalmology, neurology, and nephrology. Spherix Global Insights has expanded their coverage to assess US specialists' current understanding of the biosimilar landscape, their perceptions of biosimilars, as well as their current (where appropriate) and projected uptake of the agents. Biosimilars are due to make a more widespread appearance on the US market over the next two years, particularly as the world's top grossing drug, AbbVie's Humira (adalimumab), goes off patent in 2023.